Á¦9Àå ¼¼°èÀÇ POC(Point of Care) ºÐÀÚÁø´Ü ½ÃÀå : ¿ëµµº°
È£Èí±â °¨¿°Áõ
¼Òȱ⠰¨¿°Áõ
¼º°¨¿°Áõ
±âŸ
Á¦10Àå ¼¼°èÀÇ POC(Point of Care) ºÐÀÚÁø´Ü ½ÃÀå : ±â¼úº°
PCR
NGS/ÇÁ·Îºê
±âŸ
Á¦11Àå ¼¼°èÀÇ POC(Point of Care) ºÐÀÚÁø´Ü ½ÃÀå : Àå¼Òº°
º´¿ø
Ŭ¸®´Ð¡¤Áø·á¼Ò
³ëÀÎ ½Ã¼³
±âŸ
Á¦12Àå ¼¼°èÀÇ POC(Point of Care) ºÐÀÚÁø´Ü ½ÃÀå : Á¦Ç°º°
±â±â
īƮ¸®Áö
±âŸ
Á¦13Àå ºÎ·Ï
ksm
¿µ¹® ¸ñÂ÷
¿µ¹®¸ñÂ÷
OVERVIEW:
Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Molecular Diagnostics at the Point of Care.
Point of Care testing is proving itself in the market. Players are reporting surprising growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size out for five years.
All report data is available in Excel format on request.
Make investment decisions and valuations with confidence using the latest data.
Table of Contents
1. Market Guides
1.1. Strategic Situation Analysis
1.2. Guide for Executives, Marketing and Business Development Staff
1.3. Guide for Management Consultants and Investment Advisors
2. Introduction and Market Definition
2.1. What are Molecular Diagnostics at the Point of Care?
2.2. The Diagnostics Revolution
2.3. Market Definition
2.3.1. Revenues
2.4. Methodology
2.4.1. Methodology
2.4.2. Sources
2.4.3. Authors
2.5. Perspective: Healthcare Spending
2.5.1. Global Healthcare Spending
2.5.2. Spending on Healthcare and Pharmaceuticals
2.5.3. Spending on Diagnostics
2.5.4. Important Role of Insurance for Medical Services
3. Instrumentation, Automation and Diagnostic Trends
3.1. Instrumentation and Automation
3.1.1. Traditional Automation and Centralization
3.1.2. The New Automation, Decentralization and Point Of Care
3.1.3. Instruments Key to Market Share
3.1.4. Bioinformatics Plays a Role
3.1.5. PCR Takes Command
3.1.6. Next Generation Sequencing Fuels a Revolution
3.1.7. NGS Impact on Pricing
3.1.8. Whole Genome Sequencing, A Brave New World
3.1.9. Companion Diagnostics Blurs Diagnosis and Treatment
4. Industry Overview
4.1. Players in a Dynamic Market
4.1.1. Academic Research Lab
4.1.2. Diagnostic Test Developer
4.1.3. Instrumentation Supplier
4.1.4. Chemical/Reagent Supplier
4.1.5. Pathology Supplier
4.1.6. Independent Clinical Laboratory
4.1.7. Public National/regional Laboratory
4.1.8. Hospital Laboratory
4.1.9. Physicians Office Lab (POLS)
4.1.10. Audit Body
4.1.11. Certification Body
4.2. The Clinical Laboratory Market Segments
4.2.1. Traditional Market Segmentation
4.2.2. Laboratory Focus and Segmentation
4.3. Industry Structure
4.3.1. Hospital Testing Share
4.3.2. Economies of Scale
4.3.2.1. Hospital vs. Central Lab
4.3.3. Physician Office Lab's
4.3.4. Physician's and POCT
5. Profiles of Key MDx Companies
5.1. Abbott Laboratories
5.2. Abionic
5.3. Accelerate Diagnostics
5.4. Access Bio
5.5. Ador Diagnostics
5.6. ADT Biotech
5.7. Akonni Biosystems
5.8. Alveo Technologies
5.9. Anitoa
5.10. Applied BioCode
5.11. Aureum Diagnostics
5.12. Aus Diagnostics
5.13. Autonomous Medical Devices
5.14. Baebies
5.15. Beckman Coulter Diagnostics (Danaher)
5.16. Becton, Dickinson and Company
5.17. Binx Health
5.18. Biocartis
5.19. BioFire Diagnostics (bioMerieux)
5.20. bioMerieux Diagnostics
5.21. Bio-Rad Laboratories, Inc
5.22. Bosch Healthcare Solutions GmbH
5.23. Cepheid (Danaher)
5.24. Credo Diagnostics Biomedical
5.25. Cue Health
5.26. Curetis (OpGen)
5.27. Detect
5.28. Diagenode Diagnostics (Hologic)
5.29. Diasorin S.p.A.
5.30. DNAe
5.31. Domus Diagnostics
5.32. Enzo Biochem
5.33. Eurofins Scientific
5.34. Fluxergy
5.35. Fusion Genomics.
5.36. Genedrive
5.37. Genetic Signatures
5.38. GenMark Dx (Roche)
5.39. Genomadix
5.40. Getlabs
5.41. Global Access Diagnostics
5.42. Grip Molecular Technologies
5.43. Hologic
5.44. Immunexpress
5.45. Inflammatix
5.46. Invetech
5.47. Iollo
5.48. J&J Innovative Medicine
5.49. Karius
5.50. Lucira Health (Pfizer)
5.51. LumiraDx
5.52. Maxim Biomedical
5.53. Meep
5.54. Meridian Bioscience
5.55. Millipore Sigma
5.56. Molbio Diagnostics
5.57. NanoDx
5.58. Nanomix
5.59. Novacyt
5.60. Novel Microdevices
5.61. Novus Diagnostics
5.62. Nuclein
5.63. OnsiteGene
5.64. Operon
5.65. OraSure Technologies
5.66. Oxford Nanopore Technologies
5.67. Panagene
5.68. Prenetics
5.69. Primerdesign (Novacyt)
5.70. Prominex
5.71. Proof Diagnostics
5.72. Qiagen
5.73. QuantuMDx
5.74. QuidelOrtho
5.75. R-Biopharm AG
5.76. Response Biomedical
5.77. Revvity
5.78. Roche Diagnostics
5.79. Salignostics
5.80. SD Biosensor
5.81. Seegene
5.82. Sekisui Diagnostics
5.83. Siemens Healthineers
5.84. Sona Nanotech
5.85. SpeeDx
5.86. T2 Biosystems
5.87. Talis Biomedical
5.88. Thermo Fisher Scientific
5.89. Uniogen
5.90. Veramarx
5.91. Veredus Laboratories
5.92. XCR Diagnostics
5.93. Zhejiang Orient Gene Biotech
6. Market Trends
6.1. Factors Driving Growth
6.1.1. New Genotypes Creating New Markets
6.1.2. Aging Population a Boon for All Diagnostics
6.1.3. Developing World Driving ID Dx Growth
6.1.4. Point of Care - Why Centralization is Losing Steam